Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cancer stem-like cells (CSLCs) are involved in cancer initiation, development, and metastasis, and microRNAs (miRNAs) play pivotal roles in regulating CSLCs. miRNA-based therapeutic strategy associated with CSLCs might promise potential new therapeutic approaches. In the present study, we found that miR-1290 was increased in CD133(+) cells. Antagomir-1290 significantly suppressed tumor volume and weight initiated by CD133(+) cells in vivo. Furthermore, antagomir-1290 significantly inhibited the proliferation, clonogenicity, invasion, and migration of CD133(+) cells by targeting fyn-related Src family tyrosine kinase. These findings provide insights into the clinical prospect of miR-1290-based therapies for non-small cell lung cancer.

Original publication




Journal article


Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Publication Date





6223 - 6230


Department of Pharmacology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 5 Dongdansantiao, Beijing, 100005, People's Republic of China.


Humans, Carcinoma, Non-Small-Cell Lung, Neoplasm Invasiveness, Glycoproteins, Peptides, Neoplasm Proteins, MicroRNAs, Antigens, CD, Cell Proliferation, Cell Movement, Gene Expression Regulation, Neoplastic, Protein-Tyrosine Kinases, Neoplastic Stem Cells, Carcinogenesis, AC133 Antigen